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Abstract  
Lysosomes are degradative organelles essential for cell homeostasis that regulate a variety of 
processes, from calcium signaling and nutrient responses to autophagic degradation of 
intracellular components. Lysosomal cell death is mediated by the lethal effects of cathepsins, 
which are released into the cytoplasm following lysosomal damage. This process of lysosomal 
membrane permeabilization and cathepsin release is observed in several physiopathological 
conditions and plays a role in tissue remodeling, the immune response to intracellular pathogens 
and neurodegenerative diseases. Many evidences indicate that aging strongly influences 
lysosomal activity by altering the physical and chemical properties of these organelles, 
rendering them more sensitive to stress. In this review we focus on how aging alters lysosomal 
function and increases cell sensitivity to lysosomal membrane permeabilization and lysosomal 
cell death, both in physiological conditions and age-related pathologies.  
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1. Introduction  
Lysosomal cell death (LCD) is a cell death pathway characterized by lysosomal 
destabilization followed by the translocation of cathepsins from the lysosomal lumen to the 
cytoplasm, triggering a cascade of events that culminate in cell death. This form of regulated 
cell death can be blocked by either pharmacological or genetic inhibition of cathepsin activity 
(Aits and Jaattela, 2013; Boya and Kroemer, 2008; Serrano-Puebla and Boya, 2015). LCD is 
observed in several physiological and pathological conditions, and has been recently harnessed 
as a means of killing cancer cells (Groth-Pedersen and Jaattela, 2013; Petersen et al., 2013). 
LCD is much less frequent than other forms of cell death, such as apoptosis, and the upstream 
molecular mechanism remains largely unknown. However, lysosomal membrane 
permeabilization (LMP) that results in protease release is a key feature of LCD. The 
downstream consequences of cathepsin release include substrate degradation, caspase 
activation, and mitochondrial membrane permeabilization (MMP), all of which can be arrested 
by blocking either LMP or cathepsin activity.  
During the normal aging process lysosomes undergo various modifications that diminish 
their degradative capacity and increase their susceptibility to destabilization. In this review we 
describe new evidence of LCD regulation and discuss the age-associated decay in lysosomal 
function. We also examine how age-associated changes in lysosomes, including physical, 
biochemical, and compositional alterations, may render these organelles more vulnerable to 
stress and destabilization. Finally, we present evidence of LCD in a variety of physiological and 
pathological conditions associated with aging. 
2. Types of cell death  
2.1 Morphological classification of cell death 
 Tissue and organism homeostasis is largely sustained by cell decisions that trigger 
proliferation, differentiation, and death. Cell death often occurs during development  and it has 
been defined as programmed because occurs at precise developmental stages, in specific cell 
types, and in a stereotyped manner. Initial studies of this process focused on embryonic and 
perinatal development, and for many years the definition of cell death was based on 
morphological criteria. Historically, developmental cell death has been classified into three 
types, based on morphological criteria and how lysosomes could participate in cell demise 
(Clarke, 1990; Schweichel and Merker, 1973).  
 Type I cell death or apoptosis was characterized at the ultrastructural level by shrinkage 
and fragmentation of the cell (including the nucleus) into small bodies, which are subsequently 
engulfed by neighboring cells and degraded within the lysosomes of the engulfing cell. This 
type of cell death is by far the most common and is observed in many tissues under 
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physiological and pathological conditions (Clarke, 1990; Kerr et al., 1972). Autophagic or type 
II cell death was characterized by the formation of autophagic vacuoles, now known as 
autophagosomes in the dying cells. These are double-membrane vesicles that engulf the 
cytoplasmic components of the cell, including entire organelles, and are the main hallmark of 
the self degradation pathway known as autophagy (Kroemer, 2015). Interestingly, this form of 
cell death was observed in regions in which extensive tissue remodeling occurred. It was 
postulated that the increased activity of endolysosomes reflected their active participation in the 
degradation of intracellular components (Schweichel and Merker, 1973). Lastly, necrosis or 
type III cell death was used to describe cell death with no apparent lysosomal involvement: the 
main features used to identify this form were the disintegration of cellular structures, plasma 
membrane fragmentation, and mitochondrial swelling (Schweichel and Merker, 1973).  
 Over the years, research has highlighted the difficulties in classifying specific cell death 
subroutines based on the features of dying cells, as similar cell death morphotypes can result 
from distinct initiation cascades. Furthermore, other factors such as cell type or even cell death 
kinetics can influence the traits observed during cell death. These difficulties frequently led to 
misinterpretation (Galluzzi et al., 2012; Kroemer and Levine, 2008), prompting the 
establishment by the cell death research community of a set of guidelines, based on precise and 
measurable biochemical features, for the classification of different cell death modalities 
(Galluzzi et al., 2009). This functional classification of cell death can be easily applied in vitro. 
However, the study of programmed cell death in whole tissues or organisms remains 
challenging and mainly relies on the use of gene-deficient transgenic animals and the 
observation of morphological criteria and their consequences for cell survival. 
2.2 Biochemical and molecular classification of cell death  
 In vitro, cell death processes have been assigned to a specific subroutine using 
complementary biochemical methods that mainly rely on the inhibition of cell death using 
pharmacological or genetic approaches. According to these criteria apoptosis is usually blocked 
by caspase inhibitors, necrosis by RIP kinase inhibitors, and LCD by cathepsin inhibitors. A 
more detailed description of these cell death subroutines is provided below and illustrated in 
Figure 1. 
2.2.1 Apoptosis 
 Apoptosis is usually defined at the biochemical level as caspase-dependent cell death, 
which can be prevented by general pharmacological caspase inhibition or by overexpression of 
viral-encoded caspase inhibitors such as p35. Caspase-dependent apoptosis can be triggered by 
external cues (extrinsic apoptosis) that activate the so-called death receptors (Figure 1A). 
Caspases trigger a proteolytic cleavage cascade, ultimately leading to the activation of executor 
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caspases, such as caspase-3. In some instances caspases induce cleavage of the proapoptotic 
protein Bid, resulting in MMP, which in turn induces the loss of mitochondrial membrane 
potential, inhibition of the respiratory chain, and translocation of mitochondrial proteins to the 
cytoplasm. These mitochondrial proteins include cytochrome c, which is released into the 
cytoplasm and triggers the formation of the apoptosome, a macromolecular complex that 
activates caspase-3 (Figure 1A). In addition to extracellular signals, damage caused inside the 
cell can promote apoptotic cell death (intrinsic apoptosis). Most of these processes converge at 
the mitochondrial level, promoting apoptosome assembly or caspase-independent cell death. 
One example of the latter is cell death mediated by the mitochondrial protein AIF (apoptosis 
inducing factor), which induces DNA fragmentation and cell death (Norberg et al., 2010) 
(Figure 1A). Apoptosis is observed under many physiological settings from development to 
aging and disease states from cancer, autoimmunity to neurodegeneration.  
2.2.2 Lysosomal cell death  
Cell death induced by the LCD pathway is mediated by ectopic cathepsin activity in 
response to lysosome destabilization (Figure 1B). The permeabilization of lysosomal 
membranes facilitates the translocation of cathepsins to the cytoplasm, where they trigger a 
cascade of deleterious events that culminate in cell death (Aits and Jaattela, 2013; Boya and 
Kroemer, 2008; Brunk and Ericsson, 1972). This cell death pathway is further described below.  
2.2.3 Necroptosis 
 Necroptosis is a recent term that describes the process previously known as regulated 
necrosis (Galluzzi et al., 2012). While necrosis was long considered an uncontrolled form of 
cell death it is now clear that this process constitutes a bona fide regulated cell death pathway, 
which can be blocked by RIP kinase inhibitors (Newton, 2015). RIP kinase is activated in many 
circumstances including death receptor and toll-like receptor ligation (Figure 1C). Necroptosis 
has been observed in pathological conditions including infections, stroke, and 
neurodegenerative and inflammatory diseases (Jouan-Lanhouet et al., 2014).  
2.2.4 Autophagic and other forms of cell death 
 Autophagic cell death can be defined at the biochemical level as cell death that can be 
blocked by genetic or pharmacologic inhibition of autophagy. Less common than apoptosis, 
programmed autophagic cell death has been observed in vivo in invertebrates: autophagy-
deficient flies show marked delays in the elimination of several organs during metamorphosis 
(Zhang and Baehrecke, 2015). However, whether cell death by autophagy occurs in vivo in 
vertebrates is currently unknown. In vitro, downregulation of autophagy genes has been shown 
to block cancer cell death in several conditions (Fulda and Kogel, 2015). It is important to note 
that autophagic cell death is distinct from LCD. Although both are executed by lysosomal 
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activity (i.e. proteases) the former would also be blocked by inhibitors of the initiation phase of 
autophagy (such as 3-MA) or siRNA of autophagy genes.  
 Other less frequent forms of cell death include anoikis, which occurs when adherent cells 
lose contact with the matrix (Galluzzi et al., 2012), and mitotic catastrophe (also known as 
mitotic cell death), in which cells die during mitosis after an aberrant cell cycle or as a 
consequence of microtubule poisoning (Domenech et al., 2015). Pyroptosis is another form of 
regulated cell death characterized by caspase 1 activation and was initially observed as an 
antimicrobial response during inflammation. On detection of intracellular danger signals the cell 
activates caspase 1 after the formation of multiprotein complexes such as the inflammasome. 
Activation of the inflammasome results in the maturation and release of IL-1! and other 
cytokines and in many cases leading to cell death (Galluzzi et al., 2012).  
 
3. Lysosomal cell death  
3.1 Lysosomes  
Lysosomes are cytoplasmic membrane-enclosed organelles that degrade 
macromolecules and cell components. To execute this function these organelles contain a 
variety of hydrolytic enzymes, including proteases, lipases, nucleases, glycosidases, 
phospholipases, phosphatases, and sulfatases, which usually achieve maximal enzymatic 
activity at low pH. The acidic milieu of lysosomes (pH # 5) is maintained by a vacuolar 
ATPase, which pumps protons from the cytoplasm into the lysosomal lumen (Mindell, 2012). 
The lysosomal membrane is a single lipid bilayer protected from acidic hydrolases by the 
expression of specific membrane proteins such as LAMP-1 and LAMP-2; these heavily 
glycosylated proteins resist digestion and form a protective glycocalyx. Other lysosomal 
membrane proteins include receptors and proteins that mediate the transport of substances from 
the lysosomal lumen to the cytoplasm (Settembre et al., 2013; Wartosch et al., 2015). 
Lysosomes are found in all eukaryotic cell types, except for erythrocytes. However, not all 
lysosomes are alike. Some have acquired specific functions in certain cell types such as 
melanosomes and lytic granules, which contain modified lysosomes also known as lysosome-
related organelles (Saftig and Klumperman, 2009). The main functions of lysosomes are listed 
in Box 1.  
Lysosomes are the cell’s main catabolic organelle, and several degradation pathways 
converge at the level of these organelles. The degradation by the lysosome of extracellular 
material captured by endocytosis and phagocytosis, including plasma membrane receptors, 
extracellular matrix proteins, phagocytosed bacteria, and apoptotic cells, is known as 
heterophagy (Figure 2). If the degraded material is derived from the cell itself, the process of 
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lysosome-dependent degradation is deemed to be autophagy (Shen and Mizushima, 2014). 
Three main autophagic processes have been described to date: macroautophagy, 
microautophagy, and chaperone-mediated autophagy (CMA) (Figure 2). CMA mediates the 
transport and degradation of specific cytoplasmic proteins that harbor a specific peptide 
sequence. Microautophagy and macroautophagy deliver cellular constituents to the 
lysosome/vacuole, including large protein complexes or aggregates, organelles, invading 
pathogens such as viruses and bacteria, as well as some short-lived proteins previously thought 
to be degraded by the proteasome system  (Fuster et al., 2010; Perez-Sala et al., 2009; Shen and 
Mizushima, 2014) (Figure 2).  
Lysosome biosynthesis involves the coordinated transcription of genes that encode 
lysosomal proteins and are regulated by the transcription factor TFEB (Sardiello et al., 2009; 
Wartosch et al., 2015). Lysosomes can also be recycled from autolysosomes during the end 
stages of autophagy through autophagosome-lysosome reformation (ALR) (Yu et al., 2010). 
This process ensures the maintenance of a pool of lysosomes during periods of prolonged 
starvation that is then rapidly consumed after autophagosome-lysosome fusion. ALR begins 
with the formation from the lysosome of a tubular structure containing lysosomal membrane 
proteins such as LAMPs; this structure lacks degradative capacity and has a non-acidic pH 
(Chen and Yu, 2013). 
Other functions of the lysosome include its fusion with the plasma membrane after 
membrane damage and during wound healing, and release of the lysosomal contents into the 
extracellular space via a process called lysosomal exocytosis (Box 1). The latter has been 
observed during bone erosion, tissue remodeling, metastasis and immune cell function 
(Andrews et al., 2014; Settembre and Ballabio, 2014).  
In addition, lysosomes have been recently placed as a central coordinator in the 
responses to nutrient availability and calcium signaling (Box 1). Lysosomal membranes provide 
a physical platform for the localization of mTOR, the main sensor and master controller of cell 
and organism growth. In nutrient rich conditions a macromolecular complex, which blocks 
autophagy and phosphorylates the transcription factor TFEB is formed on the lysosomal 
surface. In starvation conditions mTOR translocates to the cytoplasm and no longer 
phosphorylates TFEB, allowing its translocation to the nucleus, where it binds to the promoter 
of many essential genes implicated in autophagy and lysosomal biogenesis (Boya, 2012; 
Settembre et al., 2013). Lysosomes also regulate TFEB via a calcium calcineurin-signaling 
pathway (Medina et al., 2015). The fine regulation of intralysosomal calcium levels underscores 
the essential role of the lysosome as a calcium store. The best known calcium channel in the 
lysosomal membrane is mucolipin 1 (also called TRPML1). This channel releases calcium from 
the lumen and regulates many aspects of lysosomal function, including trafficking, fusion with 
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other organelles, lysosomal reformation, and exocytosis (Xu and Ren, 2015). Interestingly, a 
recent study found that starvation induces a marked increase in the activity of TRPML1, leading 
to lysosomal calcium efflux, which facilitates lysosomal reformation (Wang et al., 2015). A 
new lysosome-to-nucleus signaling pathway that promotes longevity has been recently 
identified in C. elegans. Lysosomes release lipid messengers that travel to the nucleus, 
activating nuclear hormone receptors and increasing the longevity of the organism (Folick et al., 
2015). Worms fed with this lipid intermediate show an increase in life span. This pathway may 
also exist in mammals, providing a new perspective on lysosomal control of several essential 
cell signaling pathways. Last, lysosomes take an active part in cell death processes under 
physiological and pathological conditions as it is described below.   
3.2 Lysosomal membrane permeabilization and the “suicide bag” hypothesis 
 Soon after the discovery of lysosomes, Christian de Duve formulated the “suicide bag 
hypothesis”, which proposed that cell destruction and subsequent death was mediated by the 
release of lysosomal hydrolases into the cytoplasm after lysosomal membrane destabilization 
(de Duve, 1959). While this hypothesis was questioned for some time, even by de Duve himself 
(Clarke, 1990; de Duve, 1975), it is clear now that lysosomal cell death is induced in both 
physiological and pathological conditions. This regulated form of cell death can be blocked by 
pharmacological and genetic inhibition of cathepsin activity (Aits and Jaattela, 2013; Boya and 
Kroemer, 2008). The main feature of LCD is the selective and partial destabilization of the 
lysosomal membrane, a process known as lysosomal membrane permeabilization, which allows 
translocation of the lysosomal contents to the cytoplasm (Boya, 2012) (Figure 1B).  
 Despite growing interest in the mechanism by which lysosomal permeabilization causes 
cell death, the study and modulation of this phenomenon is still challenging for several reasons. 
First, lysosomes are heterogeneous organelles and their varying sensitivity to damaging agents 
means that not all lysosomes within a given cell are simultaneously permeabilized. Second, 
some caspase inhibitors, particularly at high concentrations, can also block cathepsins, resulting 
in misclassification of LCD as caspase-dependent apoptosis in some circumstances (Foghsgaard 
et al., 2001). Third, lysosomal permeabilization does not result in concrete morphological 
alterations that can be identified by electron microscopy (Brunk and Ericsson, 1972). Finally, 
some of the more powerful tools used to study LMP have only been recently developed that will 
for sure facilitate the discovery of new conditions associated to lysosomal-dependent cell death 
in the near future (Aits et al., 2015). 
3.3 Lysosomal cell death: definition and examples 
We define LCD as a cell demise pathway that results in the permeabilization of lysosomal 
membranes leading to the translocation to the cytoplasm of cathepsins, which act as executors 
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of cell death. Indeed, pharmacological or genetic inhibition of cathepsin activity protects against 
LCD. It is clear that massive release of the intraluminal contents of lysosomes triggers 
uncontrolled cell death, due in part to cytoplasmic acidification and to the degradative activity 
of lysosomal enzymes (Terman et al., 2006). However, partial and selective LMP has been 
shown to promote a cascade of events that result in controlled cell death, which can be blocked 
by cathepsin inhibitors, including cysteine and serine protease inhibitors, which primarily target 
cathepsin B and D. Interestingly, these two proteases are also active at neutral pH, supporting 
the idea of partial and selective LMP, without generalized cytoplasmic acidification (Aits and 
Jaattela, 2013; Boya and Kroemer, 2008). Thus in LCD cathepsins are considered as the main 
executors of cell demise. However under some circumstances other cell death pathways are 
engaged down stream of LMP. For example mitochondrial membrane permeabilization and/or 
caspase activation has been often observed after LMP and cathepsin release (see below). 
However and as it has been extensively demonstrated the different cell death subroutines are 
neither isolated nor mutually exclusive signaling cascades. Depending on the context a 
particular cell death subroutine can manifest biochemical features of other cell death types as 
stressors can engage multiple cell lethal mechanisms that show some degree of overlap. 
This type of cell death can be considered programmed as it has been observed in vivo in 
both physiological and pathological settings, including mammary gland involution after 
lactation, neutrophil aging, and bacterial infection (Aits and Jaattela, 2013; Serrano-Puebla and 
Boya, 2015). During mammay gland involution, gland cells are eliminated by controlled cell 
death after weaning. In the first phase of post-lactation regression, lysosomes are permeabilized 
and release cathepsin B and L into the cell cytoplasm, triggering a wave of caspase-independent 
cell death. Cathepsin mRNA expression peaks before LMP, a phenomenon dependent on the 
transcription factor Stat3 (Kreuzaler et al., 2011). Interestingly, Stat3 also regulates the switch 
in mammary gland cells from a secretory to a phagocytic phenotype and the engulfment of milk 
fat globules destabilizes lysosomal membranes, leading to cathepsin leakage and subsequent 
LCD (Sargeant et al., 2014). Thus that LMP-induced cell death contributes to tissue remodeling 
in physiological conditions. 
Neutrophils are important components of the immune system that play key roles in 
inflammatory responses to a broad spectrum of pathogens. These terminally differentiated 
cells have a limited life span, ranging from 8 h to 5 days are the first line of defense of the 
innate immune system and exert regulatory functions of adaptive immunity during infectious 
diseases (Mantovani et al., 2011). A recent study demonstrated that spontaneous neutrophil 
death is mediated by LMP and cytoplasmic release of the serine protease PR3, which promotes 
the cleavage and activation of caspase 3 and subsequent LCD (Loison et al., 2014b). Inhibition 
of LMP with the iron chelator DFO or by overexpression of Hsp70 prevents LMP, PR3 
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translocation, and cell death. Interestingly PR3-deficient mice show greater numbers of 
neutrophils in peritoneal exudates after intraperitoneal injection of E. coli, indicating reduced 
neutrophil cell death in vivo, and deletion of the endogenous inhibitor serpin accelerates 
spontaneous neutrophil death, indicating that LCD operates during in vivo neutrophil 
homeostasis (Loison et al., 2014b). Interestingly, intracellular bacteria can subvert this pathway 
to their own benefit: pyocyanin, a toxic metabolite of Pseudonomas Aeruginosa, can induce 
LMP, cathepsin translocation to the cytoplasm, and LCD of neutrophils, thus favoring bacterial 
persistence by accelerating neutrophil depletion (Prince et al., 2008). Brucella abortus, a 
pathogen that evades the innate immune response, has also been recently shown to cause cell 
death and neutropenia. The molecular mechanism underlying neutrophil cell death remains 
elusive, but appears to be independent of caspase activation, necroptosis, and pyroptosis, and 
dependent on the interaction of non-endotoxic LPS with CD14, NADP oxidase, and low 
amounts of ROS (Barquero-Calvo et al., 2015). However, direct link between LMP and 
neutrophil death remains to be definitively demonstrated. Interestingly low doses of endotoxic 
LPS have been shown to alter lysosomal function, including acidification and fusion in primary 
macrophages (Baker et al., 2015).  
LCD is beneficial for the organism in several other situations. For example, when 
Legionella pneumophila infects primary mouse macrophages, the bacterial protein RpsL 
induces macrophage release of cathepsin B, leading to macrophage cell death and the 
termination of productive infection (Zhu et al., 2015). Similarly, macrophages fight 
pneumococci through LMP, releasing cathepsin D and inducing cell death. Cathepsin 
inhibition in this system impairs bacterial clearance in the mouse lung (Bewley et al., 2011). 
Viruses that co-evolve with host cells adapt many cellular functions to their own ends, 
including LMP-induced cell death. For example, DRAM expression is upregulated in human 
immunodeficiency virus (HIV)-infected CD4+ T cells, inducing LMP-mediated death of the 
infected cell and contributing to viral infection (Laforge et al., 2013). LMP-induced cell death 
is thus a homeostatic response that helps the organism to rid itself of intracellular pathogens 
and facilitates tissue remodeling. As described below, LCD has also been described in 
numerous animal models of human diseases such as stroke, Parkinson’s disease, and 
lysosomal storage disorders (LSDs) (see Section 5).  
3.4 Inducers of lysosomal cell death 
There are many situations in which the lysosomal membrane is destabilized, promoting 
LMP and cathepsin release (Table 1). The first evidence of lysosomal destabilization was 
reported over 30 years ago when cultured cells were treated with lysosomotropic detergents 
(Firestone et al., 1979). These compounds have detergent-like properties and an affinity for the 
acidic environment of the lysosome. They accumulate after protonation and upon reaching a 
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certain concentration destabilize the lysosomal membrane (Firestone et al., 1979). In line with 
their affinity for the acidic intraluminal milieu of the lysosome, the lethal effects of these 
agents, several examples of which are provided in Table 1, are blocked by lysosomal 
basification.  
Inducing pore formation in the lysosomal membrane is the simplest way to trigger 
cathepsin release into the cytoplasm. Several venoms and bacterial toxins have this effect (Boya 
and Kroemer, 2008). VepA from the bacterium Vibrio cholerae can directly permeabilize 
isolated lysosomes and induce the release of cathepsin D, causing lysosomal death during 
infection (Matsuda et al., 2012). Pneumolysin from Streptococcus pneumoniae also has pore-
forming activity and promotes LMP leading to cathepsin B release and inflammasome 
activation in differentiated human monocytic cell lines (Bewley et al., 2014). Interestingly, in 
vivo cathepsin B inhibition is associated with better outcomes and reduced brain inflammation 
in a murine model of meningitis (Hoegen et al., 2011). Whether this effect is related to 
increased death of infected cells remains to be determined. Recent findings indicate that in 
addition to bacterial and viral proteins, endogenous toxin-like molecules such as aerolysin-like 
proteins are also capable of inducing LMP (Xiang et al., 2014). These molecules can translocate 
to lysosomes, forming high molecular-mass detergent-stable oligomers that promote lysosomal 
destabilization and cathepsin B release. Xiang and coworkers reported that this phenomenon is 
associated with increased interleukin-1! maturation and release and enhanced survival after 
bacterial infection in mice (Xiang et al., 2014).  
Like MMP, LMP has been recently shown to be regulated by members of the Bcl-2 
family of proteins. One of these proteins, Bax, translocates to lysosomal membranes after 
treatment with several inducers such as palmitate and the parkinsonian neurotoxin MPTP (Bove 
et al., 2014; Feldstein et al., 2006). Bax tranlocation to lysosomal membranes in turn induces 
LMP and cathepsin-dependent cell death (Bove et al., 2014; Kagedal et al., 2005). DRAM, 
another p53-responsive gene, induces LCD in HIV-infected cells (Laforge et al., 2013). 
Interestingly, Bax translocation to lysosomes appears to be mediated by DRAM, at least in 
some settings (Guan et al., 2015). Bim, another Bcl-2 family member also translocates to 
lysosomal membranes and induce LMP. This mechanism depends on the phosphofurin acidic 
cluster sorting protein-2 (PACS-2) a multifunctional sorting protein (Werneburg et al., 2012). 
Under what circumstances Bcl-2 family members preferentially translocate to lysosomes or 
mitochondrial membranes to induce their permeabilization and exert their lethal effects remains 
to be elucidated.  
Lysosomes do not possess enzymes such as catalase or glutathione peroxidase, which 
have the capacity to degrade hydrogen peroxide. Therefore, in response to high levels of 
oxidative stress, large amounts of hydrogen peroxide diffuse across the lysosomal membrane. 
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Lysosomes are enriched in iron, a consequence of the degradation of iron-containing molecules 
within these organelles. Fe (II) can catalyze the homolytic cleavage of hydrogen peroxide to 
form hydroxyl radicals (via the Fenton reaction), the most reactive free radicals (Terman et al., 
2006). Oxidative stress is thus one of the main causes of LMP and is observed in many 
scenarios (Table 1). This explains why the age pigment lipofuscin, which consists of oxidized 
material, usually forms within lysosomes (Terman et al., 2006) (see Section 4 below). In 
contrast to other organelles, lysosomal membranes contain high levels of the antioxidant 
vitamin E, which probably protects against high levels of hydroxyl and peroxide radicals.  
The loss of mTOR phosphorylation sites on the autophagy regulator UVRAG was 
recently shown to increase lysosome tubulation and LCD after prolonged starvation (Munson et 
al., 2015). Interestingly, this sensitizes cells to the effects of lysosomotropic detergents, 
suggesting that LCD could be a consequence of alterations in lysosomal reformation. 
Consistently, defects in ALR have been shown to induce neuronal death (Chang et al., 2014; 
Varga et al., 2015).  
Some lipids and lipidic metabolites could trigger LMP. Some of them have detergent-
like properties and subsequently act as lysosomotropic agents. This is the case of sphingosine, 
accumulated in lysosomes as the result of ceramide transformation or sphingosine kinase 1 
inhibition (Taha et al., 2005; Ullio et al., 2012). Also arachidonic acid, a lipid metabolite 
generated by phopholipase A2 (PLA2) produced LCD based on detergent-like properties 
(Zhang et al., 2006). Moreover, oxidation products of cholesterol, as 7!-hydroxycholesterol, are 
being used as LMP inducing factors in cancer cells (Roussi et al., 2007). 
Apart from being LCD effectors cathepsins could act as LMP promoters. This has been 
demonstrated by using cathepsin B-deficient fibroblast where reduced LMP is observed in 
cathepsin B-deficient cells after TNF-! treatment (Werneburg et al., 2002). Many other factors 
induce LMP, including photodamage, nanoparticles and crystals, although the specific 
underlying mechanisms remain to be elucidated (Table 1). Despite intensive research in the 
field of lysosomal death over the last decade, the precise mechanism of action of many LMP-
inducing agents is still unknown. Research in this area will likely be stimulated by recently 
developed novel investigative techniques, particularly given the potential of these factors in the 
treatment of cancer (Kirkegaard and Jaattela, 2009). 
3.5 Downstream consequences of lysosomal cell death 
The downstream consequences of LMP and cathepsin translocation depend on many 
factors, which can be cell autonomous (e.g., the intensity and duration of the stimuli) or intrinsic 
(e.g., levels of endogenous inhibitors, antioxidant defenses, and immortalization status of the 
cell) (Fehrenbacher et al., 2004). At the molecular level, one of the consequences of cathepsin 
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release after LMP is cleavage of the protein Bid. This promotes the translocation to the 
mitochondria of the proapoptotic proteins Bax and Bak which induce mitochondrial membrane 
permeabilization (MMP) and trigger caspase-dependent cell death. In many instances cathepsin 
inhibition reduces Bid cleavage, MMP, and cell death. Cathepsin activity induces the 
degradation of anti-apoptotic proteins such as XIAP and induce caspase-dependent cell death 
(Taniguchi et al., 2015). Other proteins such as Noxa can modulate LMP-dependent cell death 
(Eno et al., 2013). In many instances, amplifying loops that propagate lysosomal damage are 
observed during oxidative stress. In this scenario ROS not only target lysosomal membranes but 
also damage mitochondrial membranes, further exacerbating the oxidative stress to which 
lysosomes are subjected. These findings suggest that multiple downstream pathways are 
activated during LCD (Serrano-Puebla and Boya, 2015).  
Cancer cells often combine mutations in pro-apoptotic proteins and overexpression of 
anti-apoptotic proteins make them resistant programmed apoptotic cell death. Evidence suggests 
that cell death can still occur through LMP and lysosomotropic agents have been postulated as 
potential therapies for cancer (Kirkegaard and Jaattela, 2009). In addition cancer cells present 
modifications in lysosomes, as for example increased size, which makes them more vulnerable 
to LMP. Thus tumour cells could be be more sensible that non-tranformed cells to the toxic 
effects of lysosomotropic agents (Groth-Pedersen and Jaattela, 2013). Also approaches as 
pharmacological or genetic inhibition of endogenous stabilizers of lysosomal membrane, i.e 
Hsp70, could be successful to kill cancer cells. In this line, levels of Hsp 70 in distinct cancer 
cells lines, correlate with the response to therapies based on LMP (Mena et al., 2012). 
 
3.6 Inhibitors of lysosomal cell death 
Inhibitors of LCD are defined as molecules capable of blocking lysosome permeabilization 
cathepsin activity and the death of the cell (Figure 3). There are many examples that are able to 
rescue from cell death under many settings. These molecules can be endogenous in origin, and 
include cystatins, serpins, and Hsp70, which inhibit the action of lysosomal hydrolytic enzymes 
or stabilize the lysosomal membrane (Nylandsted et al., 2004). The internal glycocalyx of the 
lysosome also protects the membrane from the acidic pH of the lysosomal lumen and the action 
of lysosomal proteases (Settembre et al., 2013). Exogenous inhibitors such as antioxidants and 
chelators also protect against LMP. The study of LCD inhibitors, both endogenous and 
exogenous, is now an important area of research given the potential relevance of these 
compounds in to protect from disease and aging.  
3.6.1 Cystatins 
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Cystatins (cysteine protease inhibitors) are proteins that can neutralize lysosomal 
cysteine proteases such as as cathepsins. Three families of cystatins have been identified: 
stefins, (type I), cystatins (type II) and kininogens or type III cystatins (Perisic Nanut et al., 
2014; Turk and Bode, 1991). Given that their targets, cathepsins, are predominantly localized 
within lysosomes, it appears that the function of intracellular cystatins is to block the activity of 
these proteases, when released into the cytoplasm following lysosomal damage (Perisic Nanut 
et al., 2014; Turk et al., 2001). Cystatin B or stefin B (Stfb) is a cathepsin B inhibitor. Cancer 
cells in mice lacking Stfb are significantly more sensitive to treatment with the lysosomotropic 
agent Leu-Leu-OMe, suggesting an in vivo role for Stfb in protecting against cancer cell death 
(Butinar et al., 2014). Cystatin C (Cys C), also a cathepsin B inhibitor, has been shown to 
prevent cell death in PC12 cells treated with 6-OHDA (Lee et al., 2006; Lee et al., 2007). In 
N2A cells and in primary rat cortical neurons, Cys C decreases cell death following serum 
deprivation, oxidative stress, and treatment with colchicine and staurosporine (Tizon et al., 
2010).  
Studies in vivo have also demonstrated the utility of cystatins in preventing LMP and 
cell death. In a mouse model of amyotrophic lateral sclerosis (ALS) carrying the mutant 
copper/zinc superoxide dismutase (SOD1) gene, Cys C is present in motor neurons and 
astrocytes, while Cys B is found in activated microglial cells and at reduced levels in motor 
neurons, suggesting a role in motor neuron neurodegeneration (Wootz et al., 2006). The 
addition of exogenous Cys C to motor neurons of SOD1 mice in primary culture protects 
against cell death (Watanabe et al., 2014). Interestingly, in vitro and in vivo studies have 
demonstrated induction of autophagy via mTOR suggesting that beneficial effect of cystatin is 
not purely due to cathepsin inhibition (Tizon et al., 2010; Watanabe et al., 2014). In rat brain, 
analyses of endogenous cathepsin B and cystatin C have revealed changes in the expression of 
both proteins after traumatic brain injury (Martinez-Vargas et al., 2014). Moreover, 
intracerebroventricular injection of cystatin C prior to trauma exacerbates brain injury at high 
doses, but attenuates neuronal death at low doses (Martinez-Vargas et al., 2014). Interestingly, 
when crossed Cys B KO mice, a mouse model of progressive myoclonic epilepsy type 1 
(EPM1) by Cys C KO, symptoms as neuronal loss in cerebellum were exacerbated while 
crossbreeding Cys B KO mice by mice overexpressing Cys C symptoms were reversed (Kaur et 
al., 2010).  
3.6.2 Serpins 
Serpins (serine protease inhibitors) are protease inhibitors that can exert both 
extracellular and intracellular effects. Some serpins can inhibit caspases and cathepsins at the 
intracellular level and block LCD (Law et al., 2006). In C. elegans, SRP6 has prosurvival 
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function in srp6 null individuals by blocking lysosomal lysis produced by hypotonic shock and 
other insults (Luke et al., 2007). In several cancer cell lines, SCCA1, a homologue of C. elegans 
SRP-6, prevents lysosomal injury after exposure to DNA alkylating agents and hypotonic shock 
(Ullman et al., 2011).! Interestingly, despite its role in protecting against lysosomal injury, 
SCCA1 promotes cell death induced by ER stress. Finally, a recent study reported that 
SERPINB1, a PR3 inhibitor, prevents spontaneous death in aging neutrophils, and described a 
protective effect of Prtn3 knockdown in a mouse model of induced peritonitis (Loison et al., 
2014a). Neutrophil survival studies in serpin 1B knock-out mice revealed a cytoprotective role 
for this serpin function based on the inhibition of granule protease cathepsin G (Baumann et al., 
2013).  
3.6.3 Hsp70 
Heat shock protein 70, Hsp70, another endogenous protein inhibitor of LMP, is located 
at the endosomal/lysosomal membrane. This chaperone stabilizes lysosomes by binding to 
Bis(monoacylglycero)phosphate (BMP), an endosomal anionic phospholipid, and facilitates its 
binding to acid sphingomyelinase (ASM) reverting the toxic effects of siramesine, a 
lysosomotropic agent that inhibits ASM leading to lysosomal membrane permeabilization 
(Nylandsted et al., 2004; Petersen et al., 2013). Depletion of Hsp70 in cancer cells has been 
shown to trigger LMP and it can be reverted by cystein proteases inhibitors. Interestingly, 
Hsp70 expression in fibroblasts protects against TNF or etoposide induced lysosomal death 
(Nylandsted et al., 2004). Moreover, endogenous levels of Hsp70 in different cancer cell lines 
can be determinant for the resistance to polyphenol induced cathepsin leakage and cell death 
(Mena et al., 2012; Petersen et al., 2010). In cells from Niemann-Pick disease patients, 
decreased ASM activity is positively correlated with lysosomal stability, a phentoype that can 
be corrected with recombinant Hsp70 treatment (Kirkegaard et al., 2010). Thus Hsp70 plays an 
important role in preserving lysosomal membrane under many circumstances and its inhibition 
has also been suggested as a promising new strategy to fight cancer. 
3.6.4 Cathepsin inhibitors 
Pharmacological inhibitor of cathepsins as pepstatin A also block LMP in cancer cells 
following photodamage and resveratrol treatment (Marino et al., 2013; Trincheri et al., 2007). 
Another cystein protease inhibitor, E64d reduced srp-6 null C. elegans induced LMP (Luke et 
al., 2007). Both, pepstatin A and E64d, protected against death in neurons of SOD1 mice 
(Watanabe et al., 2014). Several reports demonstrate that the selective cathepsin B inhibitor  
CA-074Me is able to reduce LMP and cell death is several in vivo models such as a mouse 
model of metastatic cancer (Bechara et al., 2014), a mouse model of Kawasaki disease (Chen et 
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al., 2015) and during mammary gland involution, where it delays the regression of the gland 
after weaning (Kreuzaler et al., 2011). 
3.6.5 Antioxidants 
Antioxidants are exogenous agents commonly used to inhibit LMP and cell death, and 
do so mainly by preventing ROS-induced LMP (Zang et al., 2001). "-tocopherol has been 
shown to protect against caspase-independent apoptosis after sigma-2 ligand-induced LMP in 
cancer cells (Hornick et al., 2012), and to prevent cell death fibroblasts after LMP induction 
with siramesine, a sphingomyelinase inhibitor (Petersen et al., 2013). Another widely used 
antioxidant, N-acetylcystein (NAC), prevents cell death caused by EGCG ((-)-epigallocatechin-
3-gallate) in different cell types (Zhang et al., 2012). NAC also protects against Dp44mT-
induced toxicity (Gutierrez et al., 2014) and both caspase-dependent and caspase-independent 
cell death induced by sigma-2 ligands (Hornick et al., 2012).  
Antioxidants can also protect against photodamage-induced LMP. Trolox, an analog of 
Vitamin E, and vitamin C block ROS generation in human carcinoma cells treated with the 
photosensitizer Pc13 (Marino et al., 2013). Another photosensitizer, NPe6, produces ROS in 
photodynamic conditions, an effect prevented by treatment with vitamin C and Nac (Liu et al., 
2011). In a model of oxygen-glucose deprivation in rat hippocampal slices, both trolox and N-
tert-butyl-"-phenyl nitrone reduced ROS levels and blocked LMP (Windelborn and Lipton, 
2008). Vitamin C also protects against LMP and mitochondrial destabilization induced by 7!-
hydroxytosterol and 7!-hydroxycholesterol (Roussi et al., 2007). Finally, ebselen, another 
antioxidant and a potent scavenger of hydrogen peroxide and peroxynitrite, protects endothelial 
cells against cardiovascular stressors, stabilizing the lysosomal membrane by preventing 
cathepsin-mediated cleavage of SIRT1 (Chen et al., 2012). 
3.6.6 Ion chelators 
Ion homeostasis and membrane potential are both essential for lysosomal function, and 
modulation of these parameters is one means of preventing LCD. Lysosomal calcium regulates 
most stages of lysosomal trafficking, including lysosomal fusion to autophagosomes and late 
endosomes (Xu and Ren, 2015). Recent findings suggest that TFEB-dependent transcriptional 
regulation of autophagy and lysosomal biogenesis relies on levels of lysosomal Ca2+, which are 
controlled by the calcium channel TRPML1 (Medina et al., 2015; Xu and Ren, 2015). Calcium 
chelators have thus emerged as useful tools to protect against LMP-induced damage. Treatment 
of cancer cells with BPC induces Bax translocation to the mitochondrial membrane and 
caspase-3 activation, effects that are reversed by the calcium chelator BAPTA-AM (Bechara et 
al., 2014). Similarly, in the aforementioned C. elegans study (Luke et al., 2007), treatment of 
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srp-6 null animals with EGTA-AM or BAPTA-AM protected against death. Thus calcium 
chelators are emerging tools to protect against several injuries associated to LMP. 
Iron catalyses Fenton reactions inside the lysosome which products are highly reactive 
pro-oxidants. An imbalance in the respective concentrations of these ions could promote ROS 
formation, triggering LMP. In line with this view, various metal chelators have been shown to 
inhibit LMP. The iron chelator desferrioxamine (DFO) can block LMP induced by hydrogen 
peroxide or by other ROS inducers such as gentamycin and Dp44mT (Castino et al., 2007; 
Castino et al., 2011; Denamur et al., 2011; Gutierrez et al., 2014). The DFO derivative 
azitromycin  can also block lysosomal leakage after induction of oxidative stress in murine 
macrophages (Persson et al., 2012). LMP triggered by DNA damage following exposure to 
ionizing radiation in cancer cells is blocked by the iron chelator SIH (salicylaldehyde 
isonicotinoyl hydrazone), which also protects lung tissue from damage caused by ionizing 
radiation in cancer treatment (Berndt et al., 2010).  
Lysosomes are also the intracellular stores of other ions such as Zn2+ and Cu2+ (Xu and 
Ren, 2015). The zinc chelator TPEN (NNN’N’-tetrakis (-)(2-pyridylmethyl-ethylenediamine) 
can reverse lysosomal cell death induced by tamoxifen in severall cell types (Cho et al., 2012; 
Hwang et al., 2010). Furthermore, TPEN decreases ethambutol-induced LMP when 
simultaneously added with Zn2+ to primary rat retinal cell cultures (Chung et al., 2009). Finally, 
the copper chelator tetrathiomolibdate (TTMl) inhibits LMP after treatment with 
thiosemicarbazone (GTSM) (Stefani et al., 2015). Given that ion accumulation may increase 
ROS formation and hence cell death, chelators constitute a useful means of maintaining ion 
concentration inside lysosomes, thus preventing cell damage. Selectively directed chelators may 
also protect specific tissues from the effects of ionizing radiation used in the treatment of cancer 
(Berndt et al., 2010). 
Maintenance of lysosomal pH is essential to ensure proper function of the lysosomal 
degradation machinery. In this context, V-ATPase plays an important role in acidifying the 
lysosomal lumen and enabling the enzymatic activity of lysosomal proteins (Florey, 2015). In 
EGCG-induced LMP in cancer cells and MEFs, chloroquine, a lysosomotropic agent, rescues 
cell death by blocking LMP-induced cytosolic acidification (Zhang, 2012). Chloroquine induces 
an osmotic imbalance, increasing pH and blocking canonical autophagic flux. A recent study 
also demonstrated that chloroquine (and monensin) can induce LC3-II lipidation via a 
mechanism resembling LAP (LC3-associated phagocytosis), and that this effect is exacerbated 
by NH4Cl and blocked by the V-ATPase inhibitors Baf A and Con A (Florey et al., 2015). 
It is important to mention here a study demonstrating the protective role of DMSO 
against LMP, mitochondrial damage, and ROS formation induced by 7-OH-cholesterol in U937 
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cells (Laskar et al., 2010). Given that DMSO is widely used as a diluent, these particular effects 
should be taken into account when interpreting results from experiments in which this 
compound is used.  
In conclusions these results support the interest of cathepsins as targets for preventing 
LMP consequences. Modulation of endogenous proteins, as cystatins, serpins and Hsp70, levels 
may have some therapeutic potential: on one hand increasing cystatin levels could protect cells 
in neurodegenerative or age-related conditions, while on the other hand downregulating these 
proteins could sensitize cancer cells! to treatment with LMP inducers, potentially improving 
therapeutic outcomes. 
 
4. Age-associated lysosomal alterations: effects on lysosomal cell death 
4.1 Diminished lysosomal function with age: effects on LMP 
Free radicals are formed as a consequence of normal metabolism and accumulate 
throughout life, leading to the characteristic accumulation of oxidized proteins, lipids, and DNA 
in aged tissues. This is particularly evident in postmitotic cells in which cell division prevents 
the dilution of damaged cell components. It is now clear that aging reduces the overall 
degradative capacity of cells and is accompanied by a general decline in the activities of the 
proteasome and the lysosome (Reeg and Grune, 2015). Many factors may be responsible for the 
reduction in lysosomal activity that accompanies the aging process. As described below, some 
age-dependent alterations may render lysosomes more sensitive to stress, increasing the 
likelihood of LMP and subsequent cell death (Figure 4). 
Most cells display an age-associated increase in lysosome number and size. This 
increase in lysosomal volume has also been observed during senescence (Kurz et al., 2000) and 
is associated with enhanced fragility and increased LMP in response to various stimuli (Ono et 
al., 2003). Moreover, aged lysosomes exhibit an accumulation of undigested material. This is 
caused by oxidized macromolecules, which undergo secondary modifications that render them 
less susceptible to the action of acidic hydrolases within the lysosomes. These posttranslational 
modifications include lipid peroxidation and protein carbonylation, which promote the 
formation of highly crosslinked and oxidized material. The best known example is lipofuscin, 
also known as age pigment, which is used as a marker of aging as is readily detected owing to 
its autoflourescence. Lipofuscin preferentially accumulates inside lysosomes and its formation 
is accelerated by Fenton reactions that occur inside these organelles in response to oxidative 
stress. Evidence supports the view that increased lipofuscin accumulation within the lysosome 
may alter its degradative function (Brunk and Terman, 2002). Another possibility is that 
lipofuscin accumulation triggers lysosomal destabilization, a view supported by a recent study 
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reporting the presence of lipofuscin in the cytoplasm, probably as a consequence of LMP (Reeg 
and Grune, 2015).  
 Reduced protease activity may also contribute to the decreased degradative capacity of 
aged tissues. This could be in part due to alterations in lysosomal pH, as described in several in 
vitro and animal models of age-related pathological conditions such as Alzheimer’s disease, 
macular degeneration, and glaucoma (Guha et al., 2014a; Porter et al., 2015; Wolfe et al., 2013). 
Increasing lysosomal pH using lysosomotropic agents (e.g., certain antibiotics) induces LMP 
and cell death in several cell types (Boya et al., 2003a; Boya et al., 2003b). However, it can be 
difficult to determine intralysosomal pH in tissues, and a direct link between altered lysosomal 
pH and LCD during aging remains to be confirmed.  
An increase in calpain cleavage products has been observed during aging and has been 
linked not only to increases in calpain levels but also to alterations in the corresponding 
substrates make them more susceptible to cleavage. In many circumstances calpain lies 
upstream of cathepsin release during LCD. As such, increases in calpain activity could render 
aged cells more susceptible to LMP. Calpain has been shown to cleave many substrates that can 
increase lysosomal death by inducing LMP (e.g., LAMP-2) (Villalpando Rodriguez and 
Torriglia, 2013). A similar sequence of calpain activation, cathepsin release, and subsequent cell 
death is observed in several pathological conditions explained in section 5. 
The aforementioned findings support the view that the effects of aging on lysosomal 
function are the result of a decreased degradative capacity together with increased production of 
damaging agents. Together, these alterations sustain an amplificatory loop that further 
exacerbates the phenotype (Figure 4). Compared with younger tissue, lysosomes in aged tissues 
are larger and more fragile, which appears to make these organelles more susceptible to LMP, 
thus increasing the likelihood of tissue malfunction as a consequence of LCD.  
4.2 Age-associated alterations in lysosomal lipid composition  
Lysosomes are membrane organelles. As such, changes in the levels of lipids, which are 
the most abundant membrane components, are likely to influence lysosomal function. While the 
contribution of specific lipids to lysosomal physiology is poorly characterized, a growing body 
of evidence points to a key role in lysosomal integrity, fusion, and protein stability. Lipids may 
influence these processes not only by determining the physical properties of membranes but 
also by regulating the lateral mobility, clustering, and stability of lysosomal proteins. Several 
studies have highlighted the effects of lipids on lysosomal proteins. For example cholesterol 
levels regulate the assembly and recycling of soluble N-ethylmaleimide attachment protein 
receptor proteins (SNAREs). These transmembrane proteins assemble in complexes between 
two opposing membranes to drive the fusion process (Jahn and Scheller, 2006). Proper function 
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of lysosomal SNAREs depends on dynamic interactions, regulated by SNARE 
compartmentalization at the lysosomal membrane in cholesterol-enriched microdomains (so-
called rafts). Changes in cholesterol content alter the dynamics of SNARE interactions, 
impairing lysosomal fusion with other membranes (Fraldi et al., 2010). Indeed, decreases in 
cholesterol diminish the efficiency of lysosomal fusion with autophagosomes in in vitro fusion 
assays (Koga et al., 2010). Dynamic compartmentalization at the lysosomal membrane is also 
crucial for the function of the LAMP-2A receptor, which mediates CMA (Kaushik et al., 2006) 
(Figure 2). LAMP-2A binds to cytosolic substrates and mediates their translocation to the 
lysosomal lumen for degradation (Bandyopadhyay et al., 2008). The organization of LAMP-2A 
into multimeric complexes required for substrate translocation only occurs outside cholesterol-
enriched lipid microdomains; LAMP-2A located within these domains is susceptible to 
proteolytic cleavage and degradation (Kaushik et al., 2006). In agreement with this observation, 
decreases in lysosomal cholesterol levels result in the displacement of LAMP-2A from lipid 
rafts, increasing CMA activity, while cholesterol loading leads to LAMP-2A degradation and 
impairment of CMA (Kaushik et al., 2006). The mucolipin (TRPML1), the main lysosomal 
calcium channel, is another lysosomal protein modulated by lipids. Although the underlying 
molecular mechanisms are unclear, TRPML1 activity is inhibited by high sphingomyelin levels, 
but potentiated by sphingomyelinases (Shen et al., 2012). Accordingly, lysosomes in acid 
sphingomyelinase-deficient cells from Niemann Pick type A disease patients show reduced 
calcium release and sphingomyelin accumulation. 
Lipids also play a role in maintaining lysosomal integrity by protecting against 
membrane permeabilization. As stated above the chaperone Hsp70 contributes to lysosomal 
stabilization by binding to the endolysosomal anionic phospholipid BMP, a co-factor essential 
for sphingomyelin metabolism in lysosomes (Kirkegaard et al., 2010). This interaction enhances 
the activity of the enzyme acid sphingomyelinase, which mediates sphingomyelin catabolism. 
In line with this observation, acid sphingomyelinase deficiency leads to lysosomal membrane 
permeabilization and subsequent cytosolic release of cathepsins (Gabande-Rodriguez et al., 
2014). 
Given the central role of lipids in lysosomal physiology, a key question is whether 
lysosomal lipid composition changes with age. Research has only recently begun to address this 
question. Comparison of liver lysosomes from mice of 3 and 22 months of age has revealed 
significant lipid changes in older mice, including increased levels of cholesterol, ceramide, 
glucosylceramide, and lysophosphatidylcholine (Rodriguez-Navarro et al., 2012). Overall, 
aging promotes changes in acyl chain composition, thus increasing the levels of sphingomyelin, 
ceramide, and glucosylceramide unsaturated in both chains, as well as the percentage of 
saturated phosphatidylcholine. Short saturated sphingomyelin species are also abundant in older 
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lysosomes (Figure 4). Interestingly, many of the age-related lipid changes seen in lysosomes 
resemble those observed after dietary lipid challenge (e.g., chronic exposure to a high-fat diet or 
acute exposure to cholesterol-enriched diet) (Rodriguez-Navarro et al., 2012).  
The aforementioned findings support the view that lipid changes contribute to the decay 
of lysosomal function that accompanies aging (Figure 4). However, whether these changes 
occur in tissues other than the liver and the specific consequences in the context of aging remain 
unknown. Several hypotheses have been put forward based on current knowledge of the roles of 
lipids in lysosomal function in health and disease. It has been proposed that increased levels of 
cholesterol and short saturated forms of sphingomyelin may give rise to more rigid lipid raft 
microdomains (Rodriguez-Navarro et al., 2012). This may underlie the age-dependent decline in 
CMA (Kiffin et al., 2007) caused by decreased lysosomal levels of LAMP-2A. Previous 
analyses have ruled out changes in rates of LAMP-2A synthesis or trafficking to lysosomes in 
older organisms, and have demonstrated that LAMP-2A half-life is reduced due to accelerated 
degradation of this receptor protein (Rodriguez-Navarro et al., 2012). The reported increases in 
cholesterol and sphingomyelin in aged lysosomes may enhance the incorporation of LAMP-2 
into rafts, and hence its subsequent degradation (Kaushik et al., 2006). Increased levels of these 
lipids could also promote the sequestration of lysosomal SNAREs in lipid rafts, impairing 
SNARE fusion function (Fraldi et al., 2010). High levels of cholesterol and sphingomyelin may 
alter autophagosomal clearance by affecting the activity of lysosomal proteases (Elrick et al., 
2012) or by promoting their release into the cytoplasm due to lysosomal membrane 
permeabilization, as described in Niemann Pick disease type C and A cells (Gabande-Rodriguez 
et al., 2014). The accumulation of ceramide in lysosomes has also been associated with altered 
lysosomal enzyme activity and destabilization, as demonstrated in cells depleted of the ceramide 
export protein LAPTM4B (Blom et al., 2015). While the increase in cholesterol, sphingomyelin, 
and ceramide levels observed in aged lysosomes is moderate (5-15%), lysophosphatidylcholine 
(LysoPC) levels are markedly increased (45%) (Rodriguez-Navarro et al., 2012). It is thus 
important to note the reported ability of LysoPC to increase lysosomal permeability to 
potassium ions and protons, an effect that enhances the osmotic sensitivity of these organelles 
(Hu et al., 2007). This phenomenon could make older lysosomes more liable to destabilization 
in response to osmotic shock and less efficient in controlling their pH. Indeed, a recent study in 
yeast identified lysosomal pH as a critical regulator of aging (Hughes and Gottschling, 2012). 
The authors reported that vacuolar pH in yeast decreases with age. Given the highly conserved 
functions of the vacuole throughout evolution, it has been postulated that similar alterations may 
occur in eukaryotic lysosomes.  
Taken together these data support the view that changes in the physical and biochemical 
features of lysosomes contribute to the age-associated functional decay of these organelles. A 
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better understanding of these changes and their consequences in different tissues, as well as the 
underlying causes and molecular mechanisms, will be crucial to design strategies to combat 
LCD mechanisms triggered by aging. 
 
5. Lysosomal cell death during and in aging-related conditions  
Age-related changes with age in lysosomal system have been extensively studied in liver, where 
proteolytic pathways were more characterized. In this organ, morphological changes described 
above as enlarged lysosomal compartments, accumulation of autophagic vacuoles and 
lipofuscin deposition, occur during aging (Brunk and Terman, 2002; Terman, 1995; Vittorini et 
al., 1999). In rodents, a decreased in macroautophagic activity in liver seems to be consequence 
of both accumulation of autophagic vacuoles and hormone regulation of this type of autophagy. 
Also, in lysosomes isolated from livers of old rats, CMA has been found to be decreased 
correlating with a decrease in LAMP2A levels (Cuervo and Dice, 2000). Selective knock-in 
mice for LAMP-2A in liver, accumulate less damaged proteins, improve cellular homeostasis 
and improve liver function, thus indicating that maintenance of autophagic and lysosomal 
systems slows down age related organ failure (Zhang and Cuervo, 2008). In skeletal muscle, 
there is a progressive loss of muscle mass due to an imbalance of synthesis/degradation of 
proteins during aging. A muscle specific Atg7 knock-out mouse model, presents muscle atrophy 
and age dependent decrease in force that is enhanced after fasting or denervation (Masiero et al., 
2009).  
Another tissue showing high vulnerability to lysosomal defects with age is the brain. As 
an example, imbalance on cathepsin activities has been detected during aging process of 
neurons, contributing to neurodegeneration (Nakanishi, 2003). More precisely, levels of 
cathepsin D are increased and show extralysosomal localization in brains from old rats (Jung et 
al., 1999; Lynch and Bi, 2003). Also, a more subtle increase in cathepsin B and E activities have 
been found with age whereas a decrease in cathepsin L is observed (Nakanishi et al., 1994. 
Moreover, these changes in cathepsin levels and localization are common to neurons and glial 
cells in the brain and are restricted to areas in the brain with increased vulnerability to age-
related diseases. Another hallmark of aging lysosomes, lipofuscin, accumulates in old rat 
neurons {Oenzil, 1994 #8492). In normal human aged brain, Atg5, Atg7 and beclin1 genes are 
down-regulated indicating a defective autophagy (Lipinski et al., 2010). In studies in mouse 
retina, there is a decrease in macroautophagy (reduced mRNA expression of Beclin1 and Atg7 
as well as altered autophagic flux), accompanied by an increase in lipofuscin, ubiquitin and p62 
with age (Rodriguez-Muela et al., 2013).  
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Lysosomal alterations and LCD have been identified as key pathological events in 
diseases that develop with age, particularly neurodegenerative diseases (Serrano-Puebla and 
Boya, 2015). The aberrant accumulation of proteins is a common feature of many of these 
diseases. Strategies that enhance lysosomal clearance or enhance lysosomal biogenesis are thus 
emerging as potential therapies (Nixon, 2013).  
Atheriosclerosis is a major cause of cardiovascular disease in aged individuals. This 
chronic inflammatory process is characterized by the accumulation of modified low-density 
lipoproteins (LDL) in the arteries. These lipidic accumulations induce endothelial dysfunction 
and macrophage activation. Increased oxidative stress promotes the oxidation of LDLs to forms 
that induce LMP and cell death (Roussi et al., 2007). A recent study reported that increased 
expression of the transcription factor TFEB restores lysosomal function in macrophages and 
attenuates the deleterious effects of lipid accumulation during atherogenesis. Taken together, 
these findings suggest that lysosomal function is markedly impaired in atherosclerosis and that 
the induction of a lysosomal biogenesis program in macrophages has antiatherogenic effects 
(Emanuel et al., 2014). 
Severe lysosomal neuropathology has been described in animal models of Alzheimer’s 
disease (AD), the most common age-dependent neurodegenerative disorder, and in the brains of 
AD patients (Nixon and Yang, 2011). Different mechanisms have been proposed to explain this 
phenotype, which is associated with the accumulation of A! peptides, a key hallmark of AD. A 
recent study proposed that the deposition of extracellular !-amyloid around axons may alter 
retrograde axonal transport, and found that in several mouse models of AD this effect was 
correlated with the accumulation of altered lysosomes containing reduced levels of multiple 
soluble luminal proteases (Gowrishankar et al., 2015). Decreased levels of Hsp70 and increased 
levels of cathepsin D, LAMP-1, and ubiquitinated proteins are found in neurally-derived 
exosomes taken from AD patients prior to the onset of clinical signs (Goetzl et al., 2015). 
Furthermore, alterations in mTOR signaling and reduced autophagy in postmortem tissue from 
AD patients correlate with decreased expression of the autophagy regulator Beclin1 (Antonell et 
al., 2015; Tramutola et al., 2015). Collectively, these observations indicate alterations occurring 
at multiple levels within the endolysosomal system in AD patients. 
Early onset AD can be caused by presenilin 1 mutations, which alter lysosomal 
proteolysis and autophagy (Lee et al., 2010), leading to calcium dyshomeostasis due to 
impaired V-ATPase-mediated lysosomal acidification (Lee et al., 2015). Increases in calcium 
levels, calpain activation, and LCD are observed in many models of neuronal cell death 
including excitotoxicity and stroke (Yamashima and Oikawa, 2009). In these settings calpains 
participate in cell death by cleaving several proteins that confer lysosomal stability, including 
Hsp70 (Serrano-Puebla and Boya, 2015). It has been proposed that similar mechanisms 
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underlie LCD in AD (Yamashima, 2013). In addition, recent evidence suggests that defective 
macroautophagic turnover of brain lipids may be responsible for the deleterious effects 
observed in a mouse model of AD (Yang et al., 2014). Indeed, levels of various lipid species, 
including cholesterol and ceramide, are elevated in autophagic vacuoles and lysosomes in 
neurons of mice overexpressing mutant human amyloid precursor protein (APP). Stimulation 
of lysosomal cathepsins ameliorates lipid accumulation within these organelles (Yang et al., 
2014). Increased levels of several cathepsins, some of which show !-secretase activity in APP 
processing, have also been observed around senile plaques (Pislar et al., 2014). Interestingly, 
extracellular accumulations of cathepsins B, L, and D associated with A! deposits have been 
described in the brains of patients with AD, but not in other neurodegenerative diseases such 
as Parkinson’s or Huntington’s disease (Cataldo and Nixon, 1990). The same authors reported 
that hydrolase immunoreactivity in senile plaques is associated with lipofuscin granules in 
membrane-limiting structures, suggesting that they could be lysosomes released from neurons 
or that could remain in the tissue after neuronal death (Cataldo et al., 1991). The fact that this 
is a non-selective process, involving the release of the entire contents of the lysosome, also 
suggests that lysosomal membrane permeabilization could be involved (Cataldo et al., 1991). 
Moreover, A!1-42, the more toxic and aggregate-prone species, accumulates in the lysosomes 
of AD neurons, leading to lysosomal leakage and the release of enzymes into the cytoplasm, 
both of which correlate with morphological evidence of cellular toxicity (Yang et al., 1998),!!
Interestingly, ApoE4, the strongest genetic risk factor for late onset AD, is a lipid 
transport protein with the ability to destabilize lysosomal membranes (Ji et al., 2002). It has 
been proposed that, in response to the presence of amyloid peptide, ApoE4 forms a reactive 
molecular intermediate that binds phospholipids and becomes embedded within the lysosomal 
membrane, destabilizing it and causing lysosomal leakage and apoptosis (Ji et al., 2002). In 
summary, these findings describe multiple lysosomal alterations, including decreased stability 
and increased LCD, in AD disease models. Furthermore, alterations observed in AD patients 
support the view that LCD plays a pathogenic role in this disease.  
Pathological and genetic findings point to alterations in the autophagic lysosomal 
pathway and LCD in Parkinson’s disease (PD), another major age-related neurodegenerative 
disorder (Isacson, 2015). Decreased levels of lysosomal membrane proteins together with 
translocation of lysosomal proteases to the cytoplasm and LCD have been reported in MPTP-
treated mice, a classical model of PD (Dehay et al., 2010; Vila et al., 2011). Proper lysosomal 
function is essential to avoid the accumulation of "-synuclein, which is degraded within the 
lysosome via a process dependent on cathepsins B, L as well as by cathepsin D (McGlinchey 
and Lee, 2015; Qiao et al., 2008; Sevlever et al., 2008). Lysosomal lipid imbalance has also 
been implicated in the lysosomal pathology characteristic of PD. Mutations in the genes 
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encoding for the lysosomal glucocerebrosidase (GCase), which degrades the lipid 
glucosylceramide, are among the most common genetic risk factors for PD (Mazzulli et al., 
2011). Inhibition of the glucocerebrosidase (GCase) decreases pH-dependent autophagy and 
lysosomal degradation of "-synuclein (Mazzulli et al., 2011). Moreover, GCase enzymatic 
activity is decreased in the brains of patients with sporadic PD, leading to glucosylsphingosine 
accumulation (Rocha et al., 2015), while glucocerebrosidase gene therapy prevents "-
synucleinopathy of midbrain dopamine neurons (Rocha et al., 2015). Given that GCase 
deficiency is also observed in healthy aged individuals, it has been proposed that the aging of 
lysosomal systems occurs more rapidly in individuals at risk for PD. A recent study described a 
lipid switch that unlocks the activity of the lysosomal P-type transport ATPase ATP13A2, 
whose activity is impaired in PD. ATP13A2 activity is stimulated by its interaction with 
lysosomal signaling lipids such as phosphatidic acid and phosphatidylinositol (3,5)biphosphate 
PIP (3,5), thus protecting against "-synuclein toxicity and mitochondrial stress in cellular 
models of PD. These findings support a pathological link between lipid alterations and 
lysosomal dysfunction in PD and suggest that lysosomal enhancement may be a useful 
therapeutic strategy (Holemans et al., 2015). Further supporting this putative therapeutic role, 
the transcription factor Lmx1b, which influences the expression of the overall regulator gene for 
lysosomal biogenesis (TFEB) in dopaminergic neurons of the midbrain, is necessary to prevent 
degeneration of these neurons (Laguna et al., 2015). A similar cytoprotective effect is observed 
when TFEB is overexpressed in cellular model of MPP+ toxicity (Dehay et al., 2010).  
LCD has been observed in several retinal diseases including retinitis pigmentosa, a 
neurodegenerative condition that results in blindness caused by caspase-independent 
photoreceptor cell death (Sancho-Pelluz et al., 2008). A recent report described the pro-survival 
effect of cathepsin B and calpain inhibitors in retinal degeneration 10 (rd10) mice, which mimic 
the disease (Rodriguez-Muela et al., 2015). Because photoreceptor cells in these mice show 
LMP and enhanced cathepsin B activity, LCD has been proposed as one of the mechanisms 
underlying photoreceptor loss in inherited retinal degeneration (Rodriguez-Muela et al., 2015). 
Calpain activation has been linked to LMP and cell death in a mouse model of light-induced 
retinal degeneration (Villalpando Rodriguez and Torriglia, 2013). Interestingly, this condition is 
characterized by the degradation of LAMP-2, suggesting that lysosomal labilization may be a 
consequence of altered membrane stability. Chloroquine has been used for many years for the 
treatment of malaria and autoimmune diseases such as lupus. Chloroquine and its derivatives 
(e.g., hydroxychloroquine) become trapped inside the lysosome, increasing the pH of the 
organelle and, in cases of prolonged treatment, causing lysosomal cell death (Boya et al., 
2003b). One of the main side effects of chloroquine is retinal toxicity, which is caused by 
alterations in retinal pigment epithelial (RPE) function and leads to photoreceptor dysfunction 
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(Mahon et al., 2004). RPE cells are essential to maintain retinal homeostasis and control the 
phagocytosis of shed photoreceptor outer segments, a process by which essential components 
are degraded and recycled to sustain the visual cycle. Alterations in RPE cells are associated 
with age-dependent macular degeneration (AMD), a major cause of blindness and visual 
impairment in older adults. While no direct in vivo evidence of lysosomal membrane 
permeabilization in RPE cells has been reported, altered lysosomal function has been observed 
with age. These alterations in lysosomal function include intralysosomal accumulation of 
undigested A2E, a subproduct of the visual cycle that reduces the degradative capacity of RPE 
cells (Finnemann et al., 2002). Another age-associated change in the RPE is an increase in 
lysosomal mTOR levels, an alteration shown to decrease the rate of degradation of 
photoreceptor outer segments (Subrizi et al., 2015). Moreover, in the human ARPE-19 cell line, 
destabilization of the lysosomal membrane with lysosomotropic detergents induces LMP, 
inflammasome activation, and cell death (Tseng et al., 2013). Whether lysosomal death 
contributes to human macular degeneration remains to be elucidated.  
 Glaucoma is another age-associated retinal disease. This condition results in the death 
of retinal ganglion cells, which connect the eye to the brain, ultimately causing blindness. The 
complete molecular mechanism underlying glaucoma is yet to be fully unraveled, but damage to 
the optic nerve by for example increases in intraocular pressure has been associated to elevated 
risk of glaucoma. Dysfunction of the trabecular meshwork cells, such as that caused by age-
associated oxidative stress, also increases intraocular pressure (Liton, 2016). Interestingly, 
lysosomal damage and cathepsin D release are observed in these cells in conditions of oxidative 
stress. Importantly, the iron chelator DFO protects against cell death (Lin et al., 2010), 
suggesting that lysosomal death of trabecular meshwork cells also contributes to the aging 
phenotype of glaucoma (Liton et al., 2009). Novel therapies that target lysosomes may be 
developed for the treatment of certain retinal diseases; potential approaches include the use of 
recombinant Hsp70 (Subrizi et al., 2015) or agents that increase intralysosomal pH (Guha et al., 
2014b). 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by 
rapid motor neuron degeneration leading to muscle atrophy and paralysis (Bruijn et al., 2004). 
The SOD1G93A transgenic mouse, a widely used model of ALS, carries a human mutant Cu/Zn 
superoxide dismutase (SOD) transgene. The G93A mutation is present in about 20% of patients 
with familial ALS (fALS), and SOD1G93A mice develop motor neuron degeneration similar to 
that seen in fALS patients (Gurney et al., 1994). These mice also display alterations in the 
expression and distribution of cathepsins B, L, and D, as well as cystatins B and C (Wootz, 
2006). Cysteine C is present in the Bunina bodies of spinal motor neurons in sporadic ALS 
patients (Okamoto et al., 1993) and is decreased in the cerebrospinal fluid of ALS patients 
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(Tsuji-Akimoto et al., 2009). Moreover, Cys C protects primary cultured neurons from toxicity 
induced by mutations in SOD1. This neuroprotective action depends on both cathepsin B 
inhibition and the induction of autophagy (Watanabe et al., 2014). In both ALS patients and 
SOD1 mice mRNA levels of cathepsin B and cathepsin D are consistently increased. Moreover, 
increases in cathepsin B are observed in 90 day-old SOD1 mice, suggesting a possible role of 
cathepsin B in the early stages of the disease (Offen et al., 2009). In ALS patients, cathepsin B 
is primarily found in shrunken and pigmented neurons, a pattern that differs considerably to that 
seen in healthy control cases. By contrast, the distribution of cathepsins D, H, and L is similar in 
both groups (Kikuchi et al., 2003). Immunohistochemistry analysis in ALS patients shows a 
diffuse distribution of cathepsin B and D in in the cytoplasm rather than aggregated in 
lysosomes. This may indicate the release of cathepsin B due to lysosomal membrane 
permeabilization, although further analyses will be required to verify this hypothesis.!
 
7. Conclusions 
Cell death mechanisms play crucial roles both in tissue homeostasis and disease. A growing 
body of evidence points to LCD as an important pathway in cell demise. Although less common 
than other cell death mechanisms, LCD has been implicated in cell death in physiological 
settings (e.g., mammary gland involution), and its participation in a variety of pathological 
conditions, including infection, cancer, and neurodegenerative diseases, has stimulated research 
in this field. While the molecular mechanisms underlying LCD are not fully understood 
lysosomal permeabilization appears to play a central role. These events have been linked to the 
functional decline of lysosomes observed during physiological aging. Identifying the specific 
mechanisms involved in LCD, as well as inducers and inhibitors of this process, are important 
steps to better understanding the cellular effects of aging and disease. Novel technologies will 
help to achieve this goal, ultimately creating new avenues for the development of therapeutic 
strategies for several human diseases.  
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Figure legends 
Figure 1. Cell death pathways. (A) Apoptosis: cell death by apoptosis can be triggered by 
extrinsic signals that act on death receptors and activate caspases. Death receptors and intrinsic 
signals also activate proapoptotic members of the Bcl-2 family, such as Bid, which induce 
mitochondrial membrane permeabilization (MMP), cytochrome c release, and apoptosome 
assembly, ultimately triggering caspase-dependent cell death. Apoptosis is blocked by caspase 
inhibitors. (B) Lysosomal cell death is triggered by lysosomal membrane permeabilization 
(LMP), which results in the translocation of cathepsins to the cytoplasm and subsequent cell 
death. LMP can also be induced by oxidative stress (reactive oxygen species; ROS) and can 
generate an amplification loop, further exacerbating both LMP and MMP. Lysosomal cell death 
can be blocked by cathepsin inhibitors, antioxidants, and chelators and by endogenous 
molecules such as cystatins and serpins. (C) Necroptosis is a cell death pathway that results in 
the activation of the RIP kinase family of proteins. Necrostatin and other RIP kinase inhibitors 
protect against cell death. In several circumstances the aforementioned pathways are 
interconnected.  
 
Figure 2. Pathways that converge on lysosomes. Heterophagy delivers to the lysosomes 
material for degradation such as as bacteria, and apotptic cells. Autophagy is classified into 
several forms. Macroautophagy is characterized by the formation of an intermediate organelle, 
the autophagosome, which entraps cytoplasmic components, including entire organelles. The 
engulfed material is degraded upon fusion of the autophagosome with the lysosome. In 
chaperone-mediated autophagy proteins bearing the KFERQ motif are specifically delivered to 
the lysosome via interactions with chaperone proteins, such as Hsp70. This molecule in turn 
interacts with LAMP-2A, a receptor on the lysosomal membrane, triggering the unfolding and 
translocation of the protein inside the lysosomal lumen. Finally, microautophagy involves the 
direct transportation into the lysosome of molecules selected for degradation. 
 
Figure 3. Endogenous and exogenous inhibitors of lysosomal cell death. LAMPs and LIMPs 
are highly glycosylated proteins that form a glycocalyx, a covering which protects proteins and 
lipids from the effects of hydrolases stored within the lysosome. Expression of Hsp70 also 
protects lysosomal membranes from oxidative damage and other LMP triggers. Following their 
release into the cytosol, the activity of cathepsins can be blocked by endogenous cathepsin 
inhibitors such as cystatins and serpins. Antioxidants, chelators, and cathepsin inhibitors are the 
main exogenous inhibitors of lysosomal cell death.  
 
Figure 4. Age-associated lysosomal alterations. The figure reflects changes observed in aged 
lysosomes compared to those in non-aged (mature). Among them are lipofuscin accumulation 
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and increased size, pH and levels of certain lipids such as cholesterol, short saturated 
sphingomyelin and lysosphosphatidylcholine. These lipid changes may result in more rigid raft 
domains, which reduce the dynamic compartmentalization of SNAREs and LAMP-2. This 
could impair SNARE function and enhance LAMP-2 degradation. Sphingomyelin increase may 
also reduce the activity of the lysosomal calcium channel TRPML1. On the other hand, high 
levels of lysophosphatidylcholine could increase the permeability of the lysosomal membrane. 
Together these modifications in the membrane probably render old lysosomes more vulnerable 
to oxidative damage and permeabilization, leading to lysosomal cell death. 
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